| 28.19 -0.75 (-2.59%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.51 | 1-year : | 41.48 |
| Resists | First : | 30.4 | Second : | 35.51 |
| Pivot price | 28  |
|||
| Supports | First : | 26.12 |
Second : | 23.46 |
| MAs | MA(5) : | 28.71 |
MA(20) : | 27.39 |
| MA(100) : | 26.01 |
MA(250) : | 27.85 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 69.1 |
D(3) : | 71.8 |
| RSI | RSI(14): 56.3 |
|||
| 52-week | High : | 39.83 | Low : | 20.67 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARWR ] has closed below upper band by 46.0%. Bollinger Bands are 13.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.62 - 29.77 | 29.77 - 29.86 |
| Low: | 27.77 - 27.97 | 27.97 - 28.09 |
| Close: | 27.91 - 28.2 | 28.2 - 28.39 |
Fri, 26 Jul 2024
Arrowhead Pharmaceuticals: Driving To Commercialization (NASDAQ:ARWR) - Seeking Alpha
Fri, 26 Jul 2024
State Board of Administration of Florida Retirement System Raises Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Fri, 26 Jul 2024
HC Wainwright Research Analysts Cut Earnings Estimates for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Wed, 24 Jul 2024
Insiders At Arrowhead Pharmaceuticals Sold US$2.2m In Stock, Alluding To Potential Weakness - Simply Wall St
Wed, 24 Jul 2024
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results - Business Wire
Sun, 21 Jul 2024
US Bancorp DE Has $1.25 Million Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - American Banking and Market News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 124 (M) |
| Held by Insiders | 1.1069e+008 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 9,020 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.5785e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 335.5 % |
| Return on Equity (ttm) | -32.1 % |
| Qtrly Rev. Growth | 3.547e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -105.78 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -257 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -1.2 |
| Price to Book value | 0 |
| Price to Sales | -0.27 |
| Price to Cash Flow | 6.79 |
| Dividend | 0 |
| Forward Dividend | 8.9e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|